NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms
Corcept Therapeutics has delivered very strong long term share price gains over the past five years, yet its latest valuation checks lean more cautious, leaving investors weighing a powerful performance track record against a weak overall value score.
Corcept Therapeutics is up about 346.1% over five years, which puts the recent share price in the context of a very strong run already behind it.
Progress with cortisol modulating drugs, including Lifyorli and the resubmitted relacorilant...